[Dyslipidemia management for secondary prevention in cardiovascular disease: from guidelines to clinical practice]. in Giornale italiano di cardiologia (2006) / G Ital Cardiol (Rome). 2019 Sep;20(9 Suppl 1):44S-49S. doi: 10.1714/3219.31967.
2019
AO Cuneo
Tipo pubblicazione
Journal Article
Autori/Collaboratori (13)Vedi tutti...
Musumeci G
Ospedale Santa Croce e Carle, Cuneo.
Tarantini G
Università degli Studi, Padova.
Marchese A
Anthea Hospital GVM Care & Research, Bari.
et alii...
Abstract
Despite improvements in the treatment and prevention of risk factors (i.e. dyslipidemia), cardiovascular disease (CVD) remains one of the leading causes of morbidity and mortality in countries with a high degree of socio-economic development. As a matter of fact, in the last decades, several trials and meta-analysis highlighted the impact of treatments targeted to lowering cholesterol levels (particularly LDL-cholesterol) on outcomes of patients affected by CVD, both in terms of primary and secondary prevention. The main international CVD guidelines recommend lifestyle modifications and optimal lipid-lowering therapy in individuals with established CVD. The aim of the present document is to describe the dimension of the problem and the available therapies, offering a practical pharmacological flow-chart useful for accurate monitoring and intensive treatment of dyslipidemias in this patient population.
Accesso banca dati bibliografica
Accedi alla scheda bibliografica del documento in PUBMED
PMID : 31593190
DOI : 10.1714/3219.31967
Keywords
Secondary Prevention; Practice Guidelines as Topic; Humans; Dyslipidemias/complications/therapy; Decision Trees; Cardiovascular Diseases/etiology/prevention & control;